After eight years of poor communications on behalf of PreMD, I was frustrated with both our relationship and the lack of commercialization because these lifesaving cancer screening tests were being denied to the public
(PRWEB) October 25, 2006
ZUG, Switzerland -- Swiss-based MED-11 AG and Dr. Abulkalam M. Shamsuddin have jointly filed a Complaint for Declaratory Judgment and Breach of Contract on October 19, 2006 against PreMD, Inc. in the United States District Court for the District of Maryland (Case# 1:06-cv-02769 (CCB) Jury Trial).
Dr. Shamsuddin, Professor of Pathology at the University of Maryland and President of IP-6 Research Inc (http://www.IP-6.net), Baltimore, Maryland, is the inventor of two US patents that are the basis for cancer screening tests and monitoring kits for various cancerous and precancerous conditions. Dr. Shamsuddin licensed these patents to PreMD in a 1998 License Agreement. PreMD subsequently named the diagnostic and monitoring kits and applied to register trade-marks as 'LungAlert', 'ColorectAlert' and the 'Breast Cancer Test' in Canada.
"After eight years of poor communications on behalf of PreMD, I was frustrated with both our relationship and the lack of commercialization because these lifesaving cancer screening tests were being denied to the public", says Dr. Shamsuddin. Dr. Shamsuddin assigned the rights to the patents and the 1998 License Agreement to MED-11. According to the lawsuit, to date, PreMD has failed to recognize the assignment of rights under the License Agreement and has refused to deal with MED-11. Furthermore, PreMD declined to supply screening tests to MED-11 for conducting clinical trials or for commercialization.
According to the lawsuit, PreMD was informed of its breaches of the 1998 License Agreement; and to date these breaches have not been rectified to the satisfaction of MED-11 and Dr. Shamsuddin.
According to the lawsuit, the Complaint seeks a declaration that MED-11 is the owner of the patents; that MED-11, as Dr. Shamsuddin's assignee, has rights under the 1998 License Agreement; that PreMD has breached the terms of the 1998 License Agreement; and that the Plaintiffs are the lawful owners of all new patents and applications filed by PreMD with regard to licensed products. In addition, the Complaint seeks damages for PreMD's breaches.
MED-11 AG is an evidence-based medicine company (http://www.med-11.com) and the founding sponsor of the StatsMED Institute (http://www.statsmed.org), a non-profit organization established to represent "evidence-based medicine." MED-11 provides 10% of its ongoing revenues to StatsMED to fund clinical trials to confirm the safety and efficacy of: IP6 Plus C for reducing number and size of cancerous tumors, IP6 Plus D for lowering blood sugar levels as in diabetes, IP6 Plus I for immune support in general and in AIDS and other immunocompromised diseases in particular, IP6 Plus H for preventing and treating heart disease, IP6 Plus K for preventing and treating kidney stones, IP6 Plus O for the prevention and treatment of bone loss in osteoporosis, IP6 Protect which is used to protect against radiation damage and Sun Block Plus which protects against both UV-A and UV-B rays. All MED-11 products are supported by patents or pending patents. Additional products include Pain Relief Plus to treat arthritis and deal with inflammation.
For further information contact: Mark Peers, Chief Financial Officer: Phone: +41-41-560-8553 or Mail to: MED-11 AG, Untermüli 6, CH-6300, Zug, Switzerland.